Dexamethasone 40 mg

DRUG2 trials

Sponsors

Incyte Corporation, Janssen Research & Development, LLC

Conditions

Multiple Myeloma

Phase 2

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

CompletedNCT00639002

Incyte CorporationMultiple Myeloma

Start: 2008-03-31End: 2010-07-31Updated: 2018-02-13

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

TerminatedNCT03871829

Janssen Research & Development, LLCMultiple Myeloma

Start: 2019-05-31End: 2023-01-10Updated: 2025-03-30

Related Papers

Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.

2025-10-03

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study

Cancer Medicine2023-03-0312 citations

Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology2022-11-22109 citations

Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).

Journal of Clinical Oncology2020-05-203 citations

Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma Who Have Been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX)

Blood2019-11-133 citations

Tofacitinib Reverses Growth Promoting Effects of the Bone Marrow Stromal Environment Though Inhibition of JAK1/STAT3 Signaling in Multiple Myeloma

Blood2016-12-02